Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Ultragenyx Pharmaceutical Inc. Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and...
Updates
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
BioAge Labs, Inc. First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data...
Parkland Announces Management and Business Updates
Bob Espey, President & CEO, Announces Decision to Step DownMichael Jennings, Chair of the Board, Appointed as Executive ChairProvides Preliminary...
Dean updates trustees on Daniels School of Business; board approves department restructuring
Construction started in September on a new 164,000-square-foot Mitch Daniels School of Business facility that will be open to units...
Adaptimmune Reports Q3 2024 Financial and Business Updates
Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed...
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
--Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical...
